Clinical trial
A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus…
NCT00118768 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00118768 |
|---|---|
| Title | A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C |
| Official title | A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of the Combination of Pegylated Interferon Alfa Plus NM283 (Valopicitabine) in Treatment-Naive Patients With Chronic Hepatitis C |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | valopicitabine, Pegylated Interferon Alfa |
| Enrollment | 175 |
| Start date | Aug 1, 2005 |
| First posted | Jul 12, 2005 |
| Last update posted | Mar 2, 2009 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: